Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Du KQ"" wg kryterium: Autor


Tytuł :
Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotini
Autorzy :
Chen HF
Zhang QX
Zhu YC
Du KQ
Li XF
Wu LX
Wang WX
Xu CW
Pokaż więcej
Temat :
lung adenocarcinoma
ROS1
crizotinib
metastasis
small intestine
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
OncoTargets and Therapy, Vol Volume 11, Pp 7821-7825 (2018)
Opis pliku :
electronic resource
Relacje :
https://www.dovepress.com/intestinal-metastasis-from-primary-ros1-positive-lung-adenocarcinoma-c-peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930
Dostęp URL :
https://doaj.org/article/6320fe0aa75e46eab7e5f8ef52ee8a00
Czasopismo naukowe
Tytuł :
Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature
Autorzy :
Zhu YC
Xu CW
Ye XQ
Yin MX
Zhang JX
Du KQ
Zhang ZH
Hu J
Pokaż więcej
Temat :
Non-small cell lung cancer
EGFR gene mutation
ROS1 fusion gene
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
OncoTargets and Therapy, Vol 2016, Iss Issue 1, Pp 4301-4305 (2016)
Opis pliku :
electronic resource
Relacje :
https://www.dovepress.com/lung-cancer-with-concurrent--egfr-mutation-and-ros1-rearrangement-a-ca-peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930
Dostęp URL :
https://doaj.org/article/527d86ee343f43aeba15848141dd9cca
Czasopismo naukowe
Tytuł :
Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis
Autorzy :
Xiao HQ
Tian RH
Zhang ZH
Du KQ
Ni YM
Pokaż więcej
Temat :
non-squamous non-small-cell lung cancer
first-line
pemetrexed
chemotherapy
meta-analysis
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Źródło :
OncoTargets and Therapy, Vol 2016, Iss Issue 1, Pp 1471-1476 (2016)
Opis pliku :
electronic resource
Relacje :
https://www.dovepress.com/efficacy-of-pemetrexed-plus-platinum-doublet-chemotherapy-as-first-lin-peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930
Dostęp URL :
https://doaj.org/article/6d880f500aa749c3afe72718ae54b3c6
Czasopismo naukowe
Tytuł :
PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis.
Autorzy :
Chen HF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, China.
Wu LX; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, China.
Li XF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, China.
Zhu YC; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, China.
Pan WW; College of Medicine, Jiaxing University, Jiaxing, Zhejiang, China.
Wang WX; Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China.
Huang JH; Department of Oncology, Lishui Municipal Central Hospital, Lishui, Zhejiang, China.
Wu MH; Department of Oncology, Lishui Municipal Central Hospital, Lishui, Zhejiang, China.
Du KQ; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, China.
Pokaż więcej
Źródło :
Tumori [Tumori] 2020 Aug; Vol. 106 (4), pp. 306-311. Date of Electronic Publication: 2020 May 05.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
B7-H1 Antigen/*genetics
Thymoma/*genetics
Thymus Neoplasms/*genetics
Adult ; Aged ; B7-H1 Antigen/antagonists & inhibitors ; Biomarkers, Tumor/genetics ; Female ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Programmed Cell Death 1 Receptor/genetics ; Programmed Cell Death 1 Receptor/immunology ; Thymoma/immunology ; Thymoma/pathology ; Thymoma/therapy ; Thymus Neoplasms/immunology ; Thymus Neoplasms/therapy
Czasopismo naukowe
Tytuł :
A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Autorzy :
Chen HF; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University, Jiaxing Zhejiang 314000, People's Republic of China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou Zhejiang 310022, People's Republic of China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou Fujian 350014, People's Republic of China. Electronic address: .
Huang LC; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University, Jiaxing Zhejiang 314000, People's Republic of China.
Li XF; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University, Jiaxing Zhejiang 314000, People's Republic of China.
Lan G; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University, Jiaxing Zhejiang 314000, People's Republic of China.
Zhai ZQ; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University, Jiaxing Zhejiang 314000, People's Republic of China.
Zhu YC; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University, Jiaxing Zhejiang 314000, People's Republic of China.
Du KQ; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital,The Third Affiliated Hospital of Jiaxing University, Jiaxing Zhejiang 314000, People's Republic of China.
Lei L; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou Zhejiang 310022, People's Republic of China. Electronic address: .
Fang MY; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou Zhejiang 310022, People's Republic of China.
Pokaż więcej
Źródło :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2020 Apr; Vol. 142, pp. 59-62. Date of Electronic Publication: 2020 Feb 21.
Typ publikacji :
Case Reports; Research Support, Non-U.S. Gov't
Raport
Tytuł :
Eye metastasis in lung adenocarcinoma mimicking anterior scleritis: A case report.
Autorzy :
Chen HF; Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing 314000, Zhejiang Province, China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China.
Li XF; Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing 314000, Zhejiang Province, China.
Wu LX; Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing 314000, Zhejiang Province, China.
Zhu YC; Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing 314000, Zhejiang Province, China.
Du KQ; Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing 314000, Zhejiang Province, China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, Fujian Province, China. .
Pokaż więcej
Źródło :
World journal of clinical cases [World J Clin Cases] 2020 Jan 26; Vol. 8 (2), pp. 410-414.
Typ publikacji :
Case Reports
Raport
Tytuł :
Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors.
Autorzy :
Chen HF; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang Province, People's Republic of China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
Li XL; Department of Tumor Molecular Laboratory, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang Province, People's Republic of China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian Province, People's Republic of China. Electronic address: .
Du KQ; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang Province, People's Republic of China.
Zhu YC; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang Province, People's Republic of China.
Fang MY; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
Pokaż więcej
Źródło :
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Oct; Vol. 14 (10), pp. e217-e219.
Typ publikacji :
Case Reports; Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Mutation*
Adenocarcinoma of Lung/*drug therapy
Liver Neoplasms/*drug therapy
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Adenocarcinoma of Lung/genetics ; Adenocarcinoma of Lung/pathology ; ErbB Receptors/genetics ; Humans ; Liver Neoplasms/genetics ; Liver Neoplasms/pathology ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis
Raport
Tytuł :
A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib.
Autorzy :
Zhu YC; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, People's Republic of China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China. Electronic address: .
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, People's Republic of China. Electronic address: .
Zhuang W; Department of Medical Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, People's Republic of China.
Du KQ; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, People's Republic of China.
Chen G; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, People's Republic of China.
Lv TF; Department of Respiratory Medicine, Jinling Hospital, Nanjing, Jiangsu, People's Republic of China.
Song Y; Department of Respiratory Medicine, Jinling Hospital, Nanjing, Jiangsu, People's Republic of China.
Pokaż więcej
Źródło :
Clinical lung cancer [Clin Lung Cancer] 2019 May; Vol. 20 (3), pp. e224-e228. Date of Electronic Publication: 2019 Mar 04.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma of Lung/*genetics
Antineoplastic Agents/*therapeutic use
Lung Neoplasms/*genetics
Oncogene Proteins, Fusion/*genetics
Protein Kinase Inhibitors/*therapeutic use
Proto-Oncogene Proteins B-raf/*genetics
Vemurafenib/*therapeutic use
Adenocarcinoma of Lung/drug therapy ; Carrier Proteins/genetics ; High-Throughput Nucleotide Sequencing ; Humans ; Lung Neoplasms/drug therapy ; MAP Kinase Signaling System ; Male ; Middle Aged ; Remission Induction ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Ginsenoside compound K inhibits growth of lung cancer cells via HIF-1α-mediated glucose metabolism.
Autorzy :
Chen HF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, China.
Wu LX; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, China.
Li XF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, China.
Zhu YC; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou Zhejiang 310022, China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou Fujian 350014, China.
Huang ZZ; Department of Medical Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou Fujian 350014, China.
Du KQ; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, China.
Pokaż więcej
Źródło :
Cellular and molecular biology (Noisy-le-Grand, France) [Cell Mol Biol (Noisy-le-grand)] 2019 Apr 30; Vol. 65 (4), pp. 48-52. Date of Electronic Publication: 2019 Apr 30.
Typ publikacji :
Journal Article
MeSH Terms :
Ginsenosides/*pharmacology
Glucose/*metabolism
Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism
Lung Neoplasms/*metabolism
Lung Neoplasms/*pathology
Cell Death/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit/genetics ; Lung Neoplasms/enzymology ; Lung Neoplasms/genetics
Czasopismo naukowe
Tytuł :
Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1 -positive non-small cell lung cancer.
Autorzy :
Zhu YC; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang 314000, P.R. China.
Zhang XG; Department of Surgery, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang 314000, P.R. China.
Lin XP; Department of Pathology, Jiaxing University College of Medicine, Jiaxing, Zhejiang 314000, P.R. China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.
Li XF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang 314000, P.R. China.
Wu LX; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang 314000, P.R. China.
Chen HF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang 314000, P.R. China.
Xu CW; Department of Pathology, Fujian Provincial Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian 350014, P.R. China.
Du KQ; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang 314000, P.R. China.
Pokaż więcej
Źródło :
Oncology letters [Oncol Lett] 2019 Mar; Vol. 17 (3), pp. 3466-3474. Date of Electronic Publication: 2019 Jan 18.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.
Autorzy :
Zhu YC; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang, People's Republic of China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou Zhejiang, People's Republic of China.
Zhang QX; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou Fujian, People's Republic of China. Electronic address: .
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou Fujian, People's Republic of China. Electronic address: .
Zhuang W; Department of Medical Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Fuzhou, People's Republic of China.
Du KQ; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang, People's Republic of China.
Chen G; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou Fujian, People's Republic of China.
Lv TF; Department of Respiratory Medicine, Jinling Hospital, Nanjing Jiangsu, People's Republic of China.
Song Y; Department of Respiratory Medicine, Jinling Hospital, Nanjing Jiangsu, People's Republic of China.
Pokaż więcej
Źródło :
Clinical lung cancer [Clin Lung Cancer] 2019 Jan; Vol. 20 (1), pp. e73-e76. Date of Electronic Publication: 2018 Sep 21.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma of Lung/*drug therapy
Antineoplastic Agents/*therapeutic use
Kinesin/*genetics
Lung Neoplasms/*drug therapy
Mutation/*genetics
Oncogene Proteins, Fusion/*genetics
Protein Kinase Inhibitors/*therapeutic use
Proto-Oncogene Proteins c-ret/*genetics
Adenocarcinoma of Lung/genetics ; Aged ; Drug Resistance, Neoplasm/genetics ; ErbB Receptors/antagonists & inhibitors ; Humans ; Lung Neoplasms/genetics ; Male
Czasopismo naukowe
Tytuł :
Combined detection of CEA and CA125 for the diagnosis for lung cancer: A meta-analysis.
Autorzy :
Wu LX; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, China.
Li XF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, China.
Chen HF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, China.
Zhu YC; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou Zhejiang 310022, China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou Fujian 350014, China.
Xie DF; Department of Pathology, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, China.
Wan Y; Clinical Pathology Center, The fourth Affiliated Hospital of Anhui Medical University, Hefei Anhui 230012, China.
Du KQ; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, China.
Pokaż więcej
Źródło :
Cellular and molecular biology (Noisy-le-Grand, France) [Cell Mol Biol (Noisy-le-grand)] 2018 Dec 31; Vol. 64 (15), pp. 67-70. Date of Electronic Publication: 2018 Dec 31.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
CA-125 Antigen/*blood
Carcinoembryonic Antigen/*blood
Lung Neoplasms/*blood
Lung Neoplasms/*diagnosis
Area Under Curve ; Humans ; Publication Bias ; ROC Curve ; Sensitivity and Specificity
Czasopismo naukowe
Tytuł :
Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.
Autorzy :
Zhu YC; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, People's Republic of China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, People's Republic of China. Electronic address: .
Zhang QX; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, People's Republic of China.
Du KQ; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, People's Republic of China.
Chen G; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, People's Republic of China.
Lv TF; Department of Respiratory Medicine, Jinling Hospital, Nanjing, Jiangsu, People's Republic of China.
Song Y; Department of Respiratory Medicine, Jinling Hospital, Nanjing, Jiangsu, People's Republic of China.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2018 Dec 01; Vol. 29 (12), pp. 2392-2393.
Typ publikacji :
Case Reports; Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma of Lung/*genetics
Ataxin-7/*genetics
Crizotinib/*pharmacology
Lung Neoplasms/*genetics
Oncogene Proteins, Fusion/*genetics
Proto-Oncogene Proteins c-met/*genetics
Transcription Factors/*genetics
Adenocarcinoma of Lung/diagnosis ; Adenocarcinoma of Lung/drug therapy ; Adenocarcinoma of Lung/pathology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biopsy ; Crizotinib/therapeutic use ; Drug Resistance, Neoplasm/drug effects ; Drug Resistance, Neoplasm/genetics ; Female ; High-Throughput Nucleotide Sequencing ; Humans ; Lung Neoplasms/diagnosis ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Middle Aged ; Treatment Outcome
Raport
Tytuł :
A meta-analysis of association between serum iron levels and lung cancer risk.
Autorzy :
Chen HF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, 314000, Zhejiang Province, China.
Wu LX; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, 314000, Zhejiang Province, China.
Li XF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, 314000, Zhejiang Province, China.
Zhu YC; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, 314000, Zhejiang Province, China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang Province, China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
Xie DF; Department of Pathology, Zhejiang Rongjun Hospital, Jiaxing, 314000, Zhejiang Province, China.
Huang JH; Department of Oncology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, Lishui, 323000, Zhejiang Province, China.
Du KQ; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing, 314000, Zhejiang Province, China.
Pokaż więcej
Źródło :
Cellular and molecular biology (Noisy-le-Grand, France) [Cell Mol Biol (Noisy-le-grand)] 2018 Oct 30; Vol. 64 (13), pp. 33-37. Date of Electronic Publication: 2018 Oct 30.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Iron/*blood
Lung Neoplasms/*blood
Adult ; Aged ; Aged, 80 and over ; Humans ; Middle Aged ; Publication Bias ; Risk Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Association between BIM polymorphism and lung cancer outcomes: a meta-analysis.
Autorzy :
Li XF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China.
Wu LX; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China.
Chen HF; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China.
Zhu YC; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou Zhejiang 310022, People's Republic of China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou Fujian 350014, People's Republic of China.
Lin XP; Department of Pathology, Jiaxing University College of Medicine, Jiaxing Zhejiang 314000, People's Republic of China.
Xie DF; Department of Pathology, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China.
Du KQ; Department of Thoracic Disease Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China.
Pokaż więcej
Źródło :
Cellular and molecular biology (Noisy-le-Grand, France) [Cell Mol Biol (Noisy-le-grand)] 2018 Aug 30; Vol. 64 (11), pp. 92-96. Date of Electronic Publication: 2018 Aug 30.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Bcl-2-Like Protein 11/*genetics
Lung Neoplasms/*genetics
Polymorphism, Genetic/*genetics
Bcl-2-Like Protein 11/metabolism ; ErbB Receptors/genetics ; Female ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Male
Czasopismo naukowe
Tytuł :
Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.
Autorzy :
Zhu YC; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China.
Du KQ; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing Zhejiang 314000, People's Republic of China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou Zhejiang 310022, People's Republic of China. Electronic address: .
Song ZB; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou Zhejiang 310022, People's Republic of China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou Fujian 350014, People's Republic of China. Electronic address: .
Chen G; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou Fujian 350014, People's Republic of China.
Zhuang W; Department of Medical Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fujian Fuzhou 350014, People's Republic of China.
Lv TF; Department of Respiratory Medicine, Jinling Hospital, Nanjing Jiangsu 210002, People's Republic of China.
Song Y; Department of Respiratory Medicine, Jinling Hospital, Nanjing Jiangsu 210002, People's Republic of China.
Pokaż więcej
Źródło :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2018 Jul; Vol. 121, pp. 101-104. Date of Electronic Publication: 2018 Apr 24.
Typ publikacji :
Case Reports; Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*diagnosis
Antineoplastic Agents/*therapeutic use
Crown Ethers/*therapeutic use
Exons/*genetics
Lung Neoplasms/*diagnosis
Mutation/*genetics
Quinazolines/*therapeutic use
Adenocarcinoma/drug therapy ; Adenocarcinoma/genetics ; Aged ; Drug Resistance, Neoplasm/genetics ; ErbB Receptors/genetics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Male ; Remission Induction
Raport
Tytuł :
Clonally-related primary ALK rearranged adenocarcinoma and associated metastatic lesions.
Autorzy :
Zhu YC; Chest Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, China.
Deng YT; Department of Pathology, Tongji University Affiliated Shanghai East Hospital, Shanghai, China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China.
Zhuang W; Department of Medical Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China.
Du KQ; Chest Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, China.
Pokaż więcej
Źródło :
Thoracic cancer [Thorac Cancer] 2018 Jul; Vol. 9 (7), pp. 881-884. Date of Electronic Publication: 2018 May 08.
Typ publikacji :
Case Reports; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*diagnosis
Anaplastic Lymphoma Kinase/*genetics
Lymphatic Metastasis/*diagnosis
Adenocarcinoma/genetics ; Adenocarcinoma/pathology ; Adult ; ErbB Receptors/genetics ; Female ; Genome, Human/genetics ; Genotype ; Humans ; Lymphatic Metastasis/genetics ; Lymphatic Metastasis/pathology ; Mutation
Raport
Tytuł :
CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.
Autorzy :
Zhu YC; Chest Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, China.
Zhou YF; Department of Oncology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, Lishui, China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China.
Zhuang W; Department of Medical Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China.
Du KQ; Chest Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing, China.
Chen G; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China.
Pokaż więcej
Źródło :
Thoracic cancer [Thorac Cancer] 2018 May; Vol. 9 (5), pp. 652-655. Date of Electronic Publication: 2018 Mar 08.
Typ publikacji :
Case Reports; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma of Lung/*genetics
Microtubule-Associated Proteins/*genetics
Oncogene Proteins, Fusion/*genetics
Protein-Tyrosine Kinases/*genetics
Proto-Oncogene Proteins/*genetics
Adenocarcinoma of Lung/pathology ; High-Throughput Nucleotide Sequencing ; Humans ; Male ; Middle Aged
Raport
Tytuł :
Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib.
Autorzy :
Zhu YC; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing 314000, China.
Wang WX; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Xu CW; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China.
Tan QH; Department of Oncology, Nantong Tumor Hospital, Nantong 226361, China.
Li JY; Department of Oncology, Nantong Tumor Hospital, Nantong 226361, China.
Zhuang W; Department of Medical Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China.
Song ZB; Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Du KQ; Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, Jiaxing 314000, China.
Chen G; Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, China.
Lv TF; Department of Respiratory Medicine, Jinling Hospital, Nanjing 210002, China.
Song Y; Department of Respiratory Medicine, Jinling Hospital, Nanjing 210002, China.
Pokaż więcej
Źródło :
Journal of thoracic disease [J Thorac Dis] 2018 May; Vol. 10 (5), pp. E359-E363.
Typ publikacji :
Case Reports
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies